MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Richardson, Paul G.
Hofmeister, Craig C.
Siegel, David
Lonial, Sagar
Laubach, Jacob P.
Efebera, Yvonne A.
Vesole, David H.
Nooka, Ajay K.
Rosenblatt, Jacalyn
Raje, Noopur
Zaki, Mohamed H.
Hua, Ye
Li, Yan
Shah, Sheetal
Wang, Jianming
Anderson, Kenneth C.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1969
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Richardson, P.
    Hofmeister, C.
    Siegel, D.
    Lonial, S.
    Laubach, J.
    Efebera, Y.
    Vesole, D.
    Nooka, A.
    Rosenblatt, J.
    Raje, N.
    Zaki, M.
    Hua, Y.
    Shah, S.
    Wang, J.
    Anderson, K.
    HAEMATOLOGICA, 2013, 98 : 97 - 98
  • [2] MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)
    Richardson, Paul Gerard Guy
    Hofmeister, Craig C.
    Siegel, David Samuel DiCapua
    Lonial, Sagar
    Laubach, Jacob
    Efebera, Yvonne Adeduni
    Vesole, David H.
    Nooka, Ajay K.
    Rosenblatt, Jacalyn
    Raje, Noopur S.
    Zaki, Mohamed H.
    Hua, Ye
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN LENALIDOMIDE-REFRACTORY AND PROTEASOME INHIBITOR-EXPOSED MYELOMA: THE MM-005 TRIAL
    Richardson, P.
    Hofmeister, C.
    Raje, N.
    Siegel, D.
    Lonial, S.
    Laubach, J.
    Efebera, Y.
    Vesole, D. H.
    Nooka, A. K.
    Rosenblatt, J.
    Zaki, M. H.
    Hua, Y.
    Li, Y.
    Shah, S.
    Wang, J.
    Anderson, K. C.
    HAEMATOLOGICA, 2014, 99 : 104 - 104
  • [4] MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
    Richardson, Paul G.
    Hofmeister, Craig
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lonial, Sagar
    Laubach, Jacob
    Efebera, Yvonne Adeduni
    Vesole, David H.
    Nooka, Ajay K.
    Rosenblatt, Jacalyn
    Zaki, Mohamed H.
    Hua, Ye
    Li, Yan
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)
    Richardson, Paul C.
    Hofmeister, Craig
    Raje, Noopur S.
    Siegel, David
    Lonial, Sagar
    Laubach, Jacob P.
    Efebera, Yvonne A.
    Vesole, David H.
    Nooka, Ajav K.
    Rosenblatt, Jacalyn
    Zaki, Mohamed H.
    Herring, Jennifer
    Li, Yan
    Shah, Sheetal
    Chen, Min S.
    Anderson, Kenneth C.
    BLOOD, 2015, 126 (23)
  • [6] Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
    Richardson, Paul G.
    Rocafiguera, Albert Oriol
    Beksac, Meral
    Liberati, Anna Marina
    Galli, Monica
    Schjesvold, Fredrik
    Lindsay, Jindriska
    Weisel, Katja
    White, Darell
    Facon, Thierry
    San-Miguel, Jesus
    Sunami, Kazutaka
    O'Gorman, Peter
    Sonneveld, Pieter
    Yu, Xin
    Doerr, Thomas
    Bensmaine, Amine
    Zaki, Mohamed H.
    Anderson, Kenneth Carl
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Hofmeister, Craig C.
    Siegel, David
    Lonial, Sagar
    Zaki, Mohamad
    Hua, Ye
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth C.
    BLOOD, 2012, 120 (21)
  • [8] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [9] POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE IN PROTEASOME INHIBITOR-EXPOSED AND LENALIDOMIDE-REFRACTORY MYELOMA: RESULTS OF A MULTICENTER, DOSE-ESCALATION, PHASE 1 TRIAL (MM-005)
    Richardson, P. G.
    Hofmeister, C. C.
    Raje, N. S.
    Siegel, D. S.
    Lonial, S.
    Laubach, J.
    Efebera, Y. A.
    Vesole, D. H.
    Nooka, A. K.
    Rosenblatt, J.
    Zaki, M. H.
    Bensmaine, A.
    Herring, J.
    Li, Y.
    Shah, S.
    Chen, M. S.
    Anderson, K. C.
    HAEMATOLOGICA, 2016, 101 : 257 - 257
  • [10] MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Bensmaine, Amine
    Doerr, Thomas
    Wang, Jianming
    Zaki, Mohamed H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345